Lindsay E Bass

Insulin-binding B cells can arise in early-stage type 1 diabetes individuals in the absence of somatic hypermutation or insulin autoantibody seropositivity

The paper identifies anti-insulin B cells in early-stage T1D patients without autoantibodies or somatic hypermutation, showing their role in autoimmunity.

Transcriptionally distinct atypical B cell populations contribute to insulin autoreactivity and show differential activation, isotype switching, and somatic hypermutation in early-stage type 1 diabetes individuals

B cells from 24 early-stage type 1 diabetes individuals include four atypical clusters differing in switching and mutation; Cluster 10 had the highest insulin-binding antibody rate (5/16).

SAP loss limits anti-insulin atypical B cell activation and pro-inflammatory CD8 T cells despite preserved Tfh responses to protect against type 1 diabetes

BCL6 in T cells promotes type 1 diabetes by redirecting fates of insulin-autoreactive B lymphocytes

This paper shows that BCL6 in T cells promotes type 1 diabetes by enabling anti-insulin B cells to become pathogenic, and that blocking BCL6 in T cells prevents diabetes even when insulin-reactive B cells are present.

Prefusion-specific glycoprotein B human antibodies protect against neonatal HSV-2 infection

The paper identifies prefusion-specific human antibodies against HSV-2 gB that neutralize both HSV-1 and HSV-2 and protect neonatal mice.

A potently neutralizing and protective human antibody targeting antigenic site V on RSV and hMPV fusion glycoprotein

The paper identifies a human antibody that neutralizes RSV and hMPV by targeting a novel epitope spanning multiple antigenic sites, showing cross-protection in a mouse model.

Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity

The paper isolates glycan-reactive antibodies from HIV-1 vaccine trial participants and finds they neutralize diverse HIV strains and show broad cross-reactivity against other pathogens.